Clindamycin Injection, Solution
Product Images NDC 0404-9838

10 FDA label images from Henry Schein, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clindamycin (NDC 0404-9838). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Henry Schein, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image1.jpg (Image1)

Image1.jpg (Image1)
A warning text panel discussing Clostridium difficile-associated diarrhea (CDAD) related to antibacterial agents, including clindamycin. It highlights the severity spectrum of CDAD, cautions against clindamycin use except for serious infections, advises on necessary medical evaluations, and mentions treatment considerations if CDAD is suspected or confirmed.*
FDA Label Image

Formula1.jpg (Formula1)

Formula1.jpg (Formula1)
Chemical structure of clindamycin phosphate showing the molecular arrangement of atoms and bonds in the compound.*
FDA Label Image

Table1.jpg (Table1)

Table1.jpg (Table1)
A data table presenting predicted drug exposure of Clindamycin in adults (70 kg) and pediatric patients with postmenstrual age (PMA) ≤32 weeks or >32 to ≤40 weeks. The table shows dosage every 8 hours, AUCss0-8 hour, Cmax,ss, and Cmin,ss values with mean and standard deviation for each group.*
FDA Label Image

Image2.jpg (Image2)

Image2.jpg (Image2)
A data table titled 'Average Peak and Trough Serum Concentrations of Active Clindamycin After Dosing with Clindamycin Phosphate,' showing serum concentration levels for various dosage regimens in healthy adult males and pediatric patients. Columns include dosage regimen, peak concentration (mcg/mL), and trough concentration (mcg/mL), with details on intravenous and intramuscular dosing schedules.*
FDA Label Image

Image3.jpg (Image3)

Image3.jpg (Image3)
A table presenting dosing information for maintaining serum clindamycin levels. It details target serum levels in micrograms per milliliter, corresponding rapid infusion rates in milligrams per minute over 30 minutes, and maintenance infusion rates in milligrams per minute.*
FDA Label Image

Image4.jpg (Image4)

Image4.jpg (Image4)
A data table listing dosing information with three columns labeled Dose, Diluent, and Time. It presents different Clindamycin doses (300 mg to 1200 mg) paired with corresponding diluent volumes (50 mL to 100 mL) and infusion times (10 to 40 minutes). No additional clinical details are included.*
FDA Label Image

Image5.jpg (Image5)

Image5.jpg (Image5)
This data table lists package options for Clindamycin Injection, USP 150 mg/mL, showing NDC codes, dosage per vial or bottle, and packaging factors. It includes single-dose vials of 300 mg/2 mL, 600 mg/4 mL, and 900 mg/6 mL with 25 vials per carton, plus a 9,000 mg/60 mL pharmacy bulk package bottle with one bottle per carton.*
FDA Label Image

Label1.jpg (Label1)

Label1.jpg (Label1)
Label for Clindamycin injection, USP, 150 mg/mL strength in a 2 mL single-dose vial, providing 300 mg per vial. The label includes usage instructions for intramuscular and intravenous routes, storage conditions (20 to 25C), and packaging details. Manufactured and packaged by Henry Schein, Inc., with noted warnings and lot and expiration placeholders.*
FDA Label Image

Label2.jpg (Label2)

Label2.jpg (Label2)
Clindamycin Injection, USP 150 mg/mL in a 4 mL single dose vial, containing a total of 600 mg per 4 mL. Label indicates sterile, nonpyrogenic solution for intramuscular or intravenous use with a warning that it must be diluted before intravenous administration. The container closure is not made with natural rubber latex. Packaged by Henry Schein, Inc., with storage instructions at 20 to 25°C (68 to 77°F) and caution to keep out of children's reach. NDC 0404-9838-04 is visible along with lot and expiration placeholders.*
FDA Label Image

Label3.jpg (Label3)

Label3.jpg (Label3)
Clindamycin 150 mg/mL injection, solution, single dose vial label by Henry Schein, Inc. The label indicates 6 mL strength, for intramuscular and intravenous use, sterile and nonpyrogenic. Storage instructions specify controlled room temperature 20 to 25°C (68 to 77°F), no refrigeration. The label includes usage warnings, NDC 0404-9838, lot number, expiration, and manufacturer address in Bastian, VA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.